EA201490050A1 - Композиции и способы повышения биоэнергетического состояния женских зародышевых клеток - Google Patents
Композиции и способы повышения биоэнергетического состояния женских зародышевых клетокInfo
- Publication number
- EA201490050A1 EA201490050A1 EA201490050A EA201490050A EA201490050A1 EA 201490050 A1 EA201490050 A1 EA 201490050A1 EA 201490050 A EA201490050 A EA 201490050A EA 201490050 A EA201490050 A EA 201490050A EA 201490050 A1 EA201490050 A1 EA 201490050A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- bioenergy
- compositions
- methods
- women
- increasing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/873—Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2517/00—Cells related to new breeds of animals
- C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer
Abstract
Описаны композиции и способы, предусматривающие биоэнергетические средства для восстановления качества старых ооцитов, улучшения стволовых клеток оогониев или улучшения их производных (например, цитоплазмы или выделенных митохондрий) для применения в методиках улучшения фертильности.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161502840P | 2011-06-29 | 2011-06-29 | |
US201261600529P | 2012-02-17 | 2012-02-17 | |
PCT/US2012/033672 WO2013002880A1 (en) | 2011-06-29 | 2012-04-13 | Compositions and methods for enhancing bioenergetic status in female germ cells |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201490050A1 true EA201490050A1 (ru) | 2014-07-30 |
Family
ID=47424472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201490050A EA201490050A1 (ru) | 2011-06-29 | 2012-04-13 | Композиции и способы повышения биоэнергетического состояния женских зародышевых клеток |
Country Status (13)
Country | Link |
---|---|
US (4) | US9845482B2 (ru) |
EP (2) | EP2726601B1 (ru) |
JP (3) | JP6284475B2 (ru) |
CN (1) | CN103827293A (ru) |
AU (2) | AU2012276038B2 (ru) |
BR (1) | BR112013033797A2 (ru) |
CA (1) | CA2847292A1 (ru) |
EA (1) | EA201490050A1 (ru) |
IL (2) | IL230212B (ru) |
MX (1) | MX356815B (ru) |
UA (1) | UA117448C2 (ru) |
WO (1) | WO2013002880A1 (ru) |
ZA (1) | ZA201309707B (ru) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7955846B2 (en) | 2004-05-17 | 2011-06-07 | The General Hospital Corporation | Compositions comprising female germline stem cells and methods of use thereof |
EP2787073B1 (en) * | 2011-04-14 | 2019-03-20 | The General Hospital Corporation | Compositions and methods for autologous germline mitochondrial energy transfer |
WO2013035101A1 (en) | 2011-09-11 | 2013-03-14 | Minovia Therapeutics Ltd. | Compositions of functional mitochondria and uses thereof |
US10702556B2 (en) | 2012-05-16 | 2020-07-07 | Minovia Therpautices Ltd. | Compositions and methods for inducing angiogenesis |
ES2952032T3 (es) | 2013-03-15 | 2023-10-26 | Washington University St Louis | Administración de mononucleótido de nicotinamida en el tratamiento de ojo seco |
WO2015089656A1 (en) * | 2013-12-20 | 2015-06-25 | Fertilify Inc. | Compositions comprising vitamin c, vitamin e, and coenzyme q10 and use thereof for promoting female fertility and reproductive health |
CN104188966B (zh) * | 2014-07-14 | 2017-12-12 | 吴效科 | 小檗碱在制备治疗排卵障碍性不孕症的药物中的应用 |
US10323058B2 (en) | 2014-07-24 | 2019-06-18 | W. R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
CN104164401A (zh) * | 2014-08-12 | 2014-11-26 | 沈阳洁瑞生物技术有限公司 | 精子洗涤液及其制备方法 |
EP2995948A1 (en) * | 2014-09-09 | 2016-03-16 | Ecole Polytechnique Federale de Lausanne (EPFL) | Methods and compounds useful in hematopoietic stem cell medicine |
EP3194448A4 (en) * | 2014-09-16 | 2018-03-14 | Ovascience, Inc. | Anti-vasa antibodies, and methods of production and use thereof |
US20180057601A1 (en) * | 2014-12-24 | 2018-03-01 | Pierre Fabre Medicament | Novel humanized adam17 antibody |
US20180030413A1 (en) | 2015-02-26 | 2018-02-01 | Minovia Therapeutics Ltd. | Mammalian cells enriched with functional mitochondria |
ES2963057T3 (es) | 2015-03-09 | 2024-03-25 | Grace W R & Co | Forma cristalina de ribósido de nicotinamida |
CN104814974A (zh) * | 2015-03-16 | 2015-08-05 | 邦泰生物工程(深圳)有限公司 | 烟酰胺单核苷酸在制备抗衰老药物或保健品的应用 |
CN106244548B (zh) * | 2015-06-09 | 2019-07-05 | 成都中医药大学 | 木犀草素在诱导间充质干细胞向神经细胞定向分化中的用途 |
WO2016210232A1 (en) * | 2015-06-25 | 2016-12-29 | N.V. Perricone Llc | Niacinamide mononucleotide formulations for skin aging |
WO2017079428A1 (en) * | 2015-11-04 | 2017-05-11 | President And Fellows Of Harvard College | Site specific germline modification |
EP4252775A3 (en) | 2016-07-15 | 2023-12-20 | H2 Water Technologies Ltd | Composition for producing hydrogen rich water |
EP3517107B1 (en) * | 2016-09-26 | 2023-11-01 | St. Marianna University School of Medicine | Agent for preventing or ameliorating reduction in ovarian function |
CA3044814A1 (en) * | 2016-11-29 | 2018-06-07 | Charles M. Brenner | Use of nad precursors for improving maternal health and/or offspring health |
US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
RU2662983C1 (ru) * | 2017-01-31 | 2018-07-31 | Алексей Юрьевич Грязнов | Культуральная среда для ооцитов и эмбрионов |
WO2018143258A1 (ja) * | 2017-01-31 | 2018-08-09 | オリエンタル酵母工業株式会社 | 多分化能性幹細胞増殖促進剤 |
TW201835326A (zh) * | 2017-03-02 | 2018-10-01 | 美商歐瑞3恩公司 | 用於使用誘導性多能幹細胞之後代中的輔助繁殖及基因缺陷預防的系統及方法 |
WO2018200357A1 (en) * | 2017-04-26 | 2018-11-01 | Elysium Health, Inc. | Methods and compositions of improving fertility |
US20200179441A1 (en) * | 2017-04-27 | 2020-06-11 | H2 Water Technologies Ltd. | Synergistic compositions for increasing mitochondrial function and energy |
US11179423B2 (en) * | 2017-05-31 | 2021-11-23 | Palo Alto Investors | Methods of enhancing female fertility |
CN107308200A (zh) * | 2017-06-19 | 2017-11-03 | 北正赛欧(北京)生物科技有限公司 | 用于治疗宫颈癌的组合物及其应用 |
CA3071561A1 (en) * | 2017-07-31 | 2019-02-07 | Newsouth Innovations Pty Limited | Methods for increasing fertility |
BR112020005489A2 (pt) | 2017-09-22 | 2020-09-24 | Jubilant Epipad Llc, | composto da fórmula (i), composto de fórmula (ii), composto de fórmula (iii), processo de preparação de compostos de fórmula (i), processo de preparação de compostos de fórmula (ii), processo de preparação de compostos de fórmula (iii), composição farmacêutica, método para inibir uma ou mais famílias pad em uma célula, método para tratar uma afeção mediada por um ou mais pads, utilização do composto, método para o tratamento e/ou prevenção de uma afeção mediada por um ou mais distúrbios da família pad, método para o tratamento de artrite reumatoide e método de tratamento de câncer |
MX2020003341A (es) | 2017-10-18 | 2020-09-17 | Jubilant Epipad LLC | Compuestos de imidazo-piridina como inhibidores de pad. |
US11629135B2 (en) | 2017-11-06 | 2023-04-18 | Jubilant Prodell Llc | Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation |
CN111542523B (zh) | 2017-11-24 | 2024-03-29 | 朱比连特埃皮斯科瑞有限责任公司 | 作为prmt5抑制剂的杂环化合物 |
CN108384751A (zh) * | 2018-03-12 | 2018-08-10 | 山大生殖研发中心有限公司 | 卵母细胞体外成熟培养方法和培养基 |
AU2019234185A1 (en) | 2018-03-13 | 2020-10-01 | Jubilant Prodel LLC. | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation |
CN108642001B (zh) * | 2018-05-08 | 2022-09-02 | 中国农业科学院北京畜牧兽医研究所 | 一种提高牛性控冻精体外受精能力的方法 |
EP3794005A1 (en) * | 2018-05-15 | 2021-03-24 | Jumpstart Fertility Pty Ltd | Inorganic salts of nicotinic acid mononucleotide as anti-aging agents |
EP3823640A4 (en) | 2018-07-22 | 2022-05-18 | Minovia Therapeutics Ltd. | MITOCHONDRIAL AUGMENTATION THERAPY OF MUSCULAR DISEASES |
WO2020028684A1 (en) * | 2018-08-01 | 2020-02-06 | Jumpstart Fertility Pty Ltd | Salts of nicotinic acid and nicotinamide as anti-aging agents |
JP2021533195A (ja) * | 2018-08-01 | 2021-12-02 | ジャンプスタート ファーティリティ ピーティーワイ リミテッド | 抗老化剤としてのニコチン酸及びニコチンアミドモノヌクロエチド及びリボシドの四級アンモニウム塩 |
CA3122246A1 (en) * | 2018-12-05 | 2020-06-11 | Celagenex Research (India) Pvt. Ltd. | Synergistic compositions of bioactive agents for optimizing cellular health |
CN109674808A (zh) * | 2019-01-30 | 2019-04-26 | 四川大学 | β-烟酰胺单核苷酸或其前体在制备延缓肺衰老药物中的用途 |
CN111617093A (zh) * | 2019-06-13 | 2020-09-04 | 中国科学院广州生物医药与健康研究院 | 化合物在制备药物中的用途 |
US20220315889A1 (en) * | 2019-06-17 | 2022-10-06 | The Brigham And Women's Hospital, Inc. | Materials and methods for generating functional oocytes |
WO2020262325A1 (ja) * | 2019-06-28 | 2020-12-30 | 国立大学法人広島大学 | 雌の抗老化剤 |
JP2023512605A (ja) * | 2020-02-03 | 2023-03-27 | ファイト テック コーポレーション | エルゴチオネインの使用に関連する方法および組成物 |
WO2021168419A1 (en) * | 2020-02-20 | 2021-08-26 | Northeastern University | Methods and compositions for use of mitochondrial therapies to improve female reproductive potential |
JP7289042B2 (ja) * | 2020-03-04 | 2023-06-09 | パナソニックIpマネジメント株式会社 | 洗濯機 |
TWI753404B (zh) * | 2020-04-16 | 2022-01-21 | 國立屏東科技大學 | 輸卵管幹細胞促進卵母細胞體外成熟和胚發育之製劑、製備方法及其用途 |
CN111500531A (zh) * | 2020-05-15 | 2020-08-07 | 扬州大学 | 一种鸡PGCs在体外长期培养的方法 |
WO2021247776A1 (en) * | 2020-06-02 | 2021-12-09 | Mediwel Labs, LLC | Biologically active compositions and methods of using |
KR20230066015A (ko) * | 2020-09-08 | 2023-05-12 | 고쿠리츠다이가쿠호진 히로시마다이가쿠 | 정자 운동성 개선제 및 정자 운동성 개선 방법 |
CN111925986B (zh) * | 2020-09-24 | 2021-01-19 | 深圳市一五零生命科技有限公司 | 一种脐带间充质干细胞无血清培养基及其制备方法 |
CN114561342A (zh) * | 2020-11-27 | 2022-05-31 | 童国庆 | Nad信号通路激动剂在体外胚胎培养中的应用 |
EP4281131A1 (en) * | 2021-01-19 | 2023-11-29 | Gallant Pet, Inc. | Methods for optimizing reproductive tissue derived cell yield and viability for clinical applications |
CN115074388B (zh) * | 2021-06-29 | 2023-04-28 | 北京大学深圳医院 | 母源因子诱导的2c样全能干细胞及其转化应用 |
CN113403264A (zh) * | 2021-07-21 | 2021-09-17 | 中国农业大学 | 一种gv期冷冻卵母细胞解冻后体外成熟培养液及其应用 |
CN113599371A (zh) * | 2021-09-06 | 2021-11-05 | 郑州大学 | 二甲双胍在制备预防胸腺退化和/或促进胸腺组织再生药物中的应用 |
CN113797186A (zh) * | 2021-10-27 | 2021-12-17 | 宁夏医科大学 | 二甲双胍在激活雌性生殖干细胞的应用 |
CN113750242A (zh) * | 2021-10-28 | 2021-12-07 | 复旦大学附属中山医院 | Nmn联合cd38抑制剂在制备预防或治疗阿霉素所致心脏毒性药物中的应用 |
TW202334089A (zh) | 2021-11-02 | 2023-09-01 | 美商夫雷爾醫療公司 | Pparg反向激動劑及其用途 |
CN115247146A (zh) * | 2021-12-31 | 2022-10-28 | 温州医科大学 | 一种人类胚胎体外培养基及提高体外培养人类胚胎发育潜能的方法 |
JP2023156553A (ja) * | 2022-04-13 | 2023-10-25 | 克昭 團 | 卵巣機能活性化剤、抗老化剤、医薬品、化粧品および食品または飲料 |
CN114917215B (zh) * | 2022-04-27 | 2024-01-23 | 中国科学院生物物理研究所 | 活性化合物预防或治疗卵巢功能障碍性疾病的用途 |
CN115590017B (zh) * | 2022-11-04 | 2023-09-12 | 中国农业大学 | 一种通过降低线粒体温度提高卵母细胞冷冻效果的方法 |
CN115956506B (zh) * | 2023-02-16 | 2023-11-03 | 云南省农业科学院茶叶研究所 | 一种茶树离体再生组织的构建方法 |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE285564C (ru) | 1913-07-25 | |||
US3854470A (en) | 1973-11-23 | 1974-12-17 | L Augspurger | Reproduction processes for cellular bodies |
IT1057895B (it) | 1975-02-17 | 1982-03-30 | Serono Lab | Gonadotropina corionica umana parzialmente desalinizzata per indurre l'ouvulazione |
FR2322860A1 (fr) | 1975-09-05 | 1977-04-01 | Aron Sarl | Procede de preparation de chlorhydrate de dimethylbiguanide |
US4193392A (en) | 1977-09-23 | 1980-03-18 | Barnett Gordon R | Method for removing ova from animals |
US4326505A (en) | 1980-01-07 | 1982-04-27 | Occidental Petroleum Corporation | Surgical procedure for embryo transplants on animals |
US4339434A (en) | 1981-08-17 | 1982-07-13 | Gametrics Limited | Method of increasing the incidence of female offspring |
US4845077A (en) | 1984-04-03 | 1989-07-04 | Serono Laboratories, Inc. | Method of inducing ovulation |
FR2563726B1 (fr) | 1984-05-04 | 1986-10-10 | Robert Cassou | Appareil d'insemination artificielle, notamment des carnivores |
US4642094A (en) | 1984-05-29 | 1987-02-10 | North Jr Walter L | Non-surgical embryo transfer device |
US4589402A (en) | 1984-07-26 | 1986-05-20 | Serono Laboratories, Inc. | Method of in vitro fertilization |
US4725579A (en) | 1985-02-21 | 1988-02-16 | Serono Laboratories, Inc. | Method of in vitro fertilization by a unique combination of gonadotropins |
FR2580933B1 (fr) | 1985-04-24 | 1987-08-07 | Lenck Lucien | Capacite trans-uterine pour fecondation " in vitro in vivo " |
FR2589879B1 (fr) | 1985-11-08 | 1989-05-12 | Claude Ranoux | Conteneur pour culture anaerobie d'embryons humains |
AT387718B (de) | 1986-04-09 | 1989-03-10 | Fischl Franz H Dr | Katheder zur kuenstlichen befruchtung |
FR2608037A1 (fr) | 1986-12-10 | 1988-06-17 | Lenck Lucien | Methode d'intubation destinee a permettre la transplantation de l'oeuf ou de la matiere embryonnaire, et moyens pour sa mise en oeuvre |
FR2609885B1 (fr) | 1987-01-22 | 1989-04-14 | Cassou Robert | Instrument pour l'insemination artificielle, le transfert d'embryons ou le prelevement de liquides folliculaires chez les mammiferes |
US5538948A (en) | 1987-01-30 | 1996-07-23 | Novo Nordisk A/S | Method for treating infertility comprising administering GnRH analog, gonadotrophins, and growth hormone |
US4865589A (en) | 1987-04-22 | 1989-09-12 | Ludwig Simmet | Instrument for the transfer of materials such as sperm and embryos |
FR2614626B1 (fr) | 1987-04-30 | 1989-07-21 | Ranoux Claude | Conteneur pour fecondation des ovocytes et replacement des embryons chez l'homme et l'animal |
US5160312A (en) | 1990-02-09 | 1992-11-03 | W. R. Grace & Co.-Conn. | Cryopreservation process for direct transfer of embryos |
US5147315A (en) | 1990-04-06 | 1992-09-15 | C. R. Bard, Inc. | Access catheter and system for use in the female reproductive system |
US5627066A (en) | 1991-05-14 | 1997-05-06 | Mount Sinai School Of Medicine Of The City University Of New York | Method and apparatus for in vitro fertilization |
JPH06507565A (ja) | 1991-05-14 | 1994-09-01 | マウント シナイ スクール オヴ メディスン オヴ ザ シティー ユニバーシティー オヴ ニューヨーク | 体外受精方法および装置 |
FR2678506B1 (fr) | 1991-07-01 | 2000-03-10 | Claude Ranoux | Procede de fecondation en cycle spontane. |
US5296375A (en) | 1992-05-01 | 1994-03-22 | Trustees Of The University Of Pennsylvania | Mesoscale sperm handling devices |
US5744366A (en) | 1992-05-01 | 1998-04-28 | Trustees Of The University Of Pennsylvania | Mesoscale devices and methods for analysis of motile cells |
GB9227123D0 (en) | 1992-12-30 | 1993-02-24 | Applied Research Systems | Method |
US5563059A (en) | 1993-02-23 | 1996-10-08 | Genentech, Inc. | Use of human inhibin and human activin to increase the number of mature primate oocytes |
GB9305984D0 (en) | 1993-03-23 | 1993-05-12 | Royal Free Hosp School Med | Predictive assay |
US5360389A (en) | 1993-05-25 | 1994-11-01 | Chenette Philip E | Methods for endometrial implantation of embryos |
US5541081A (en) | 1994-03-22 | 1996-07-30 | President And Fellows Of Harvard College | Process for assessing oocyte and embryo quality |
GB9410639D0 (en) | 1994-05-27 | 1994-07-13 | Queen Mary & Westfield College | Method of improving fertilization |
US5716928A (en) | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
JP3660026B2 (ja) | 1995-09-04 | 2005-06-15 | 扶桑薬品工業株式会社 | 体外受精用培地組成物 |
US5827174A (en) | 1995-09-26 | 1998-10-27 | Reuss, Jr.; William Alexander | Biological speciman containment and incubation pouch |
US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
US6007839A (en) | 1996-02-16 | 1999-12-28 | The Liposome Company, Inc. | Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes |
US6040340A (en) | 1996-05-07 | 2000-03-21 | Schering Aktiengesellschaft | Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors |
US5824548A (en) | 1996-05-29 | 1998-10-20 | Wisconsin Alumni Research Foundation | Method of increasing survival of cultured primate embryos in medium containing exogenous gonadotrophin releasor hormone |
DE69738806D1 (de) * | 1996-10-10 | 2008-08-14 | Invitrogen Corp | Tierzellkulturmedium mit pflanzlichen nährstoffen |
CA2199663C (en) | 1997-03-11 | 2004-08-10 | Ruth Miriam Moses | In vitro maturation and fertilization of mammalian oocytes |
US5935968A (en) | 1997-03-17 | 1999-08-10 | Merck & Co., Inc. | Methods for treating polycystic ovary syndrome |
EP1005327A1 (en) | 1997-07-02 | 2000-06-07 | Sdg, Inc. | Targeted liposomal constructs for diagnostic and therapeutic uses |
US5961444A (en) | 1997-10-17 | 1999-10-05 | Medworks Corporation | In vitro fertilization procedure using direct vision |
US6010448A (en) | 1997-10-17 | 2000-01-04 | Medworks Corp | Embryo transfer arrangement |
US6196965B1 (en) | 1998-05-21 | 2001-03-06 | Cryofacets, Inc. | Compositions methods and devices for embryo implantation for in vitro fertilization |
BR0008468A (pt) | 1999-02-24 | 2002-02-05 | Novo Nordisk As | Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos |
ATE361091T1 (de) | 1999-02-24 | 2007-05-15 | Novo Nordisk As | Behandlung von unfruchtbarkeit |
AU1123301A (en) * | 1999-10-27 | 2001-05-08 | General Hospital Corporation, The | Methods and compositions for enhancing developmental potential of oocytes and zygotes |
EP1233978A4 (en) | 1999-11-18 | 2003-07-23 | Brigham & Womens Hospital | COMPOSITIONS AND METHODS FOR IMPROVED DIAGNOSIS AND TREATMENT OF GERM CELL TUMORS |
US6875854B1 (en) | 1999-11-18 | 2005-04-05 | The Brigham And Women's Hospital, Inc. | Compositions and methods for the improved diagnosis and treatment of germ cell tumors |
US6544166B1 (en) | 1999-11-25 | 2003-04-08 | Groendahl Christian | Treatment of human infertility |
US6762053B2 (en) * | 2000-06-09 | 2004-07-13 | Vitrolife, Inc. | Mammalian gamete and embryo culture media and culture media supplements |
FR2812004B1 (fr) | 2000-07-24 | 2002-12-27 | Ccd Lab | Milieux de culture pour fecondation in vitro, ou pour la culture de follicules, cellules germinales males ou embryons |
US7226994B2 (en) | 2001-01-18 | 2007-06-05 | Cambridge University Technical Services Limited | Cell surface expressed marker of pluripotency |
IL152904A0 (en) * | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
US20060025337A1 (en) | 2003-07-01 | 2006-02-02 | President And Fellows Of Harvard College | Sirtuin related therapeutics and diagnostics for neurodegenerative diseases |
EP1648437A2 (en) | 2003-07-01 | 2006-04-26 | President And Fellows Of Harvard College | Sirt1 modulators for manipulating cell/organism lifespan/stress response |
WO2005007687A1 (en) | 2003-07-09 | 2005-01-27 | Dana-Farber Cancer Institute, Inc | Compositions and methods for modulating ovarian follicular initiation |
US20050130302A1 (en) | 2003-09-29 | 2005-06-16 | Reprocell Inc. | Method and composition for regulating expansion of stem cells |
JP2007527418A (ja) | 2003-12-29 | 2007-09-27 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 肥満及びインシュリン耐性障害を治療又は防止するための組成物 |
SI1765085T1 (sl) | 2004-05-17 | 2015-11-30 | The General Hospital Corporation | Sestavki, ki vsebujejo ženske zarodne matične celice in postopki njihove uporabe |
US7955846B2 (en) * | 2004-05-17 | 2011-06-07 | The General Hospital Corporation | Compositions comprising female germline stem cells and methods of use thereof |
JP2008501343A (ja) * | 2004-06-04 | 2008-01-24 | ワシントン・ユニバーシティ | 神経障害を治療するための方法および組成物 |
JP2008527002A (ja) * | 2005-01-13 | 2008-07-24 | サートリス ファーマシューティカルズ, インコーポレイテッド | 神経変性障害および血液凝固障害を予防および処置するための新規組成物 |
CA2610854A1 (en) * | 2005-03-30 | 2006-10-05 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
US20090137681A1 (en) | 2005-04-08 | 2009-05-28 | David A Sinclair | Sirtuin Inhibiting Compounds |
US20080050347A1 (en) * | 2006-08-23 | 2008-02-28 | Ichim Thomas E | Stem cell therapy for cardiac valvular dysfunction |
WO2008026018A1 (en) * | 2006-09-01 | 2008-03-06 | Topotarget Switzerland Sa | New method for the treatment of inflammatory diseases |
US20120135091A1 (en) * | 2007-01-18 | 2012-05-31 | Roth Mark B | Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides |
WO2008157398A1 (en) | 2007-06-13 | 2008-12-24 | Litron Laboratories Ltd. | Method for measuring in vivo hematotoxicity with an emphasis on radiation exposure assessment |
US20090111764A1 (en) | 2007-10-25 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Mitochondrial selection |
US8415094B2 (en) * | 2007-12-21 | 2013-04-09 | Jaffar Ali bin M. Abdullah | Protein-free gamete and embryo handling and culture media products |
NO331476B1 (no) * | 2007-12-21 | 2012-01-16 | Jaffar Ali Bin M Abdullah | Proteinfri gamete- og embryo-handtering samt dyrkningsmedieprodukter inneholdende metylcellulose |
WO2009087568A2 (en) | 2008-01-10 | 2009-07-16 | Universidade De Coimbra | Compositions comprising antioxidant and mitoprotective flavonoids with neuroprotective properties |
EP2213288A1 (en) | 2009-01-30 | 2010-08-04 | Karl Welte | NAMPT and vitamin B3 for treating or preventing diseases |
US8903660B2 (en) | 2010-06-24 | 2014-12-02 | The Invention Science Fund I, Llc | Rejuvenation or preservation of germ cells |
US8338178B2 (en) | 2010-10-28 | 2012-12-25 | The Invention Science Fund I, Llc | Mitochondrial enhancement of cells |
JP2012105585A (ja) * | 2010-11-17 | 2012-06-07 | Nippon Ika Kikai Seisakusho:Kk | 人工受精用組成物 |
EP2787073B1 (en) | 2011-04-14 | 2019-03-20 | The General Hospital Corporation | Compositions and methods for autologous germline mitochondrial energy transfer |
AU2012276037A1 (en) | 2011-06-29 | 2014-02-13 | Mayo Foundation For Medical Education And Research | Small molecule CD38 inhibitors and methods of using same |
-
2012
- 2012-04-13 CN CN201280040259.8A patent/CN103827293A/zh active Pending
- 2012-04-13 AU AU2012276038A patent/AU2012276038B2/en not_active Ceased
- 2012-04-13 MX MX2014000201A patent/MX356815B/es active IP Right Grant
- 2012-04-13 UA UAA201400826A patent/UA117448C2/uk unknown
- 2012-04-13 EP EP12804411.2A patent/EP2726601B1/en not_active Not-in-force
- 2012-04-13 US US13/447,083 patent/US9845482B2/en active Active
- 2012-04-13 BR BR112013033797A patent/BR112013033797A2/pt active Search and Examination
- 2012-04-13 EA EA201490050A patent/EA201490050A1/ru unknown
- 2012-04-13 EP EP18203134.4A patent/EP3495470A1/en not_active Withdrawn
- 2012-04-13 JP JP2014518556A patent/JP6284475B2/ja not_active Expired - Fee Related
- 2012-04-13 WO PCT/US2012/033672 patent/WO2013002880A1/en active Application Filing
- 2012-04-13 CA CA2847292A patent/CA2847292A1/en not_active Abandoned
-
2013
- 2013-12-20 ZA ZA2013/09707A patent/ZA201309707B/en unknown
- 2013-12-26 IL IL230212A patent/IL230212B/en active IP Right Grant
-
2015
- 2015-02-26 US US14/632,754 patent/US20160024527A1/en not_active Abandoned
-
2017
- 2017-06-13 JP JP2017116146A patent/JP6496359B2/ja not_active Expired - Fee Related
- 2017-10-27 AU AU2017251852A patent/AU2017251852A1/en not_active Abandoned
- 2017-11-17 US US15/816,647 patent/US20180100166A1/en not_active Abandoned
-
2018
- 2018-03-14 IL IL258129A patent/IL258129A/en unknown
- 2018-07-13 US US16/034,446 patent/US20190002919A1/en not_active Abandoned
- 2018-10-29 JP JP2018202431A patent/JP2019030326A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2017251852A1 (en) | 2017-11-16 |
US20130059384A1 (en) | 2013-03-07 |
JP2019030326A (ja) | 2019-02-28 |
BR112013033797A2 (pt) | 2017-02-14 |
JP2017206526A (ja) | 2017-11-24 |
IL258129A (en) | 2018-05-31 |
AU2012276038A1 (en) | 2014-02-20 |
ZA201309707B (en) | 2019-09-25 |
WO2013002880A4 (en) | 2013-02-21 |
MX356815B (es) | 2018-06-07 |
JP2014520526A (ja) | 2014-08-25 |
EP2726601A4 (en) | 2015-04-15 |
EP2726601A1 (en) | 2014-05-07 |
IL230212B (en) | 2018-08-30 |
JP6496359B2 (ja) | 2019-04-03 |
CN103827293A (zh) | 2014-05-28 |
US20160024527A1 (en) | 2016-01-28 |
CA2847292A1 (en) | 2013-01-03 |
AU2012276038B2 (en) | 2017-08-31 |
US20190002919A1 (en) | 2019-01-03 |
US9845482B2 (en) | 2017-12-19 |
EP2726601B1 (en) | 2018-12-26 |
JP6284475B2 (ja) | 2018-02-28 |
US20180100166A1 (en) | 2018-04-12 |
UA117448C2 (uk) | 2018-08-10 |
MX2014000201A (es) | 2014-06-11 |
WO2013002880A1 (en) | 2013-01-03 |
EP3495470A1 (en) | 2019-06-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201490050A1 (ru) | Композиции и способы повышения биоэнергетического состояния женских зародышевых клеток | |
EA201391523A1 (ru) | Композиции и способы для переноса энергии митохондрий аутологичных герминативных клеток | |
BR112014018524A2 (pt) | derivados de pirimido [4,5-b]indol e métodos de utilização dos mesmos na expansão de células-tronco hematopoiéticas, composição farmacêutica e kits | |
CL2017003456A1 (es) | Metodos para tratar tumores de celulas epitelioides | |
BR112013028907A2 (pt) | conjugados de proteína-agente ativo e método para preparar os mesmos | |
IN2014MN01879A (ru) | ||
EA201270300A1 (ru) | Визуализация и оценка эмбрионов, яйцеклеток и стволовых клеток | |
BR112014006176A8 (pt) | Rna transcrito in vitro ou rna sintético, composição, método para gerar uma população de células t geneticamente modificadas por rna, e, uso de uma célula t geneticamente modificada | |
AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
CR20140185A (es) | Derivados de (4-fenilimidazol-2-il)etilamina útiles como moduladores de canal de sodio | |
BR112014009031A2 (pt) | formulações de etanercept estabilizadas com íons de metais | |
UY33970A (es) | Derivados de ácido 3-fenilpropiónico ramificados y su uso | |
MY175260A (en) | Prion free nanoparticle compositions and methods of making thereof | |
MX359639B (es) | Metodos y composiciones para uso en tratamientos celulares. | |
CO2017002506A2 (es) | Nuevos activadores de la guanilato ciclasa soluble y su uso | |
DOP2012000239A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
EA201990032A1 (ru) | Способы и композиции для терапии посредством потенциирования стволовых клеток | |
UA111357C2 (ru) | Аналоги эпоксиэйкозатриеновой кислоты, композиция на их основе, применение для лечения заболеваний и способ снижения гипертонии и нефротоксичности (варианты) | |
UY32704A (es) | Compuestos de 2,3-dihidro-1h-indeno | |
BR112015021147A2 (pt) | métodos e detergentes enzimáticos para remoção de biomembranas | |
WO2017015245A8 (en) | Methods and compositions for stem cell transplantation | |
UA113540C2 (xx) | Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду | |
BR112016005509A8 (pt) | método de preparação de um extrato de sementes de urucum (anato), composição, extrato vegetal, e composição farmacêutica | |
EA201490363A1 (ru) | Новые составы на основе (триметоксифениламино)пиримидинилов | |
EA201791233A1 (ru) | Материал стволовых клеток и способ его получения |